True North Advisors LLC Invests $1.72 Million in Elevance Health, Inc. (NYSE:ELV)

True North Advisors LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,654 shares of the company’s stock, valued at approximately $1,717,000.

Other large investors also recently modified their holdings of the company. Raelipskie Partnership purchased a new stake in Elevance Health during the 3rd quarter worth approximately $26,000. PSI Advisors LLC acquired a new stake in shares of Elevance Health during the third quarter worth approximately $27,000. Eastern Bank acquired a new stake in Elevance Health in the third quarter valued at $31,000. Dunhill Financial LLC boosted its stake in Elevance Health by 57.8% during the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock valued at $37,000 after acquiring an additional 26 shares during the last quarter. Finally, Peterson Financial Group Inc. acquired a new position in Elevance Health during the 3rd quarter worth $44,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ELV. Stephens cut shares of Elevance Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $520.00 to $440.00 in a research report on Wednesday. StockNews.com raised Elevance Health from a “hold” rating to a “buy” rating in a research report on Friday, January 17th. Mizuho lowered their target price on shares of Elevance Health from $585.00 to $505.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Argus lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Friday, October 18th. Finally, Wells Fargo & Company dropped their price objective on shares of Elevance Health from $593.00 to $495.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Elevance Health has an average rating of “Moderate Buy” and a consensus target price of $524.87.

Elevance Health Stock Performance

Shares of ELV opened at $390.21 on Thursday. The firm has a market capitalization of $90.50 billion, a PE ratio of 14.23, a P/E/G ratio of 1.09 and a beta of 0.84. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $386.73 and a 200 day moving average price of $464.16. Elevance Health, Inc. has a 52-week low of $362.21 and a 52-week high of $567.26.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.